Hi,
ranbaxy remains a blue chip in ne long term investment portfolios.
The company is trying to make headways in US generics market,facing resistance thru litigation..
This has impacted its bottomline
But the company continues to stress on its R&D division which will help it show improvement in Fy07 with launch of its products.
In the other international markets it is growing thru inorganic growth..Hence a true global presence
Technically the scrip has faced resistence at rs 400
Presently close to that..if it manages to go beyond that u may set targets at higher price but amitda has mentioned in one of his posts recently that it may be in for some more correction..
Hard call since dont know much of ur entry point of investment horizon..
Regards
ML